文献速递肺结节与肺癌

Foritinib治疗中国ROS1重排晚期非小细胞肺癌:多中心开放标签单臂2期研究

Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
PubMed 文献 · Lancet Respir Med · 2024-07-23

该2期研究评估了新型ALK/ROS1抑制剂Foritinib在ROS1重排晚期NSCLC患者中的疗效与安全性。在ROS1抑制剂初治患者中,客观缓解率在2a期为94%、2b期为88%;基线脑转移患者中2b期客观缓解率达90%。3-4级治疗相关不良事件发生率为32%,最常见为高血糖和QT间期延长。

要点

  • Foritinib在ROS1抑制剂初治的ROS1重排NSCLC中显示高客观缓解率。
  • 基线脑转移患者中也观察到颅内抗肿瘤活性。
  • 常见3-4级不良事件为高血糖和QT间期延长,需监测。

核心结论

  • Foritinib在ROS1抑制剂初治的ROS1重排NSCLC患者中显示出全身和颅内抗肿瘤活性及良好耐受性。

研究设计与样本

  • 多中心、开放标签、单臂2期研究,分2a和2b两部分,在中国29个中心进行。
  • 纳入年龄≥18岁、组织学或细胞学确认的ROS1重排、局部晚期或转移性IIIB-IV期NSCLC、ECOG体能状态≤2的患者。
  • 2a期纳入未接受或接受过一种ROS1抑制剂的患者,2b期队列1纳入ROS1抑制剂初治患者。
  • 2a期患者接受80、120、160或210 mg Foritinib琥珀酸口服每日一次,21天为一周期;2b期患者接受推荐2期剂量160 mg。
  • 主要终点为独立评审委员会评估的客观缓解率,全分析集为至少接受一剂研究治疗的所有参与者。

主要发现

  • 2020年3月26日至2022年12月29日,共104例患者入组并接受治疗。
  • 疗效分析集(n=98)包括2a期42例(17例ROS1抑制剂初治,25例既往接受过ROS1抑制剂)和2b期队列1的56例。
  • 2a期ROS1抑制剂初治患者客观缓解率为94%(95% CI 71-100;17例中16例),既往接受过ROS1抑制剂患者为40%(21-61;25例中10例)。
  • 2b期队列1客观缓解率为88%(95% CI 76-95;56例中49例)。
  • 基线脑转移患者中,2a期ROS1抑制剂初治客观缓解率为100%(95% CI 48-100;5例中5例),2a期既往接受过ROS1抑制剂为40%(16-68;15例中6例),2b期队列1为90%(70-99;21例中19例)。

临床怎么用

  • Foritinib可作为ROS1抑制剂初治的ROS1重排晚期NSCLC患者的潜在治疗选择,尤其对基线脑转移患者。
  • 治疗期间需监测高血糖和QT间期延长等不良事件。

局限性

  • 单臂设计,无对照比较。
  • 2a期部分患者既往接受超过一种ROS1抑制剂,但被排除在疗效分析外。
  • 研究仍在进行中,长期生存数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently approved targeted treatment for ROS1-rearranged non-small-cell lung cancer (NSCLC) has either inadequate intracranial activity or CNS-related toxicities. We evaluated the efficacy and safety of foritinib, a novel ALK and ROS1 inhibitor, in patients with advanced ROS1-rearranged NSCLC. METHODS: This two-part (phase 2a and 2b), multicentre, single-arm, open-label, phase 2 study was done in 29 centres in China. Eligible participants were adults (aged ≥18 years) with histologically or cytologically confirmed ROS1-rearranged, locally advanced or metastatic stage IIIB-IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 2 or less. Patients who had previously received no or one ROS1 inhibitor were enrolled into phase 2a, and patients who were naive to ROS1 inhibitor therapy were enrolled into phase 2b cohort 1. Participants in phase 2a received 80, 120, 160, or 210 mg foritinib succinate (foritinib) orally once daily over 21-day cycles; patients in phase 2b received the recommended phase 2 dose of 160 mg. The primary endpoint was objective response rate, assessed by the independent review committee in the full analysis set (ie, all participants who received at least one dose of study treatment). The safety analysis set included all participants who received at least one dose of study treatment and had available safety assessments. This study is ongoing and is registered with ClinicalTrials.gov, NCT04237805. FINDINGS: Between March 26, 2020, and Dec 29, 2022, 104 patients were enrolled and treated. Six patients who had previously received more than one ROS1 inhibitor were enrolled in phase 2a before a protocol amendment stating that patients in this phase should have received no more than one ROS1 inhibitor; these patients were included in the safety analysis but excluded from the efficacy analysis of the ROS1-inhibitor-pretreated cohort. Therefore, the efficacy analysis set (n=98) included 42 patients from phase 2a (17 who were ROS1 inhibitor naive and 25 who had previously received ROS1 inhibitor) and 56 patients from phase 2b cohort 1. In phase 2a, the objective response rate was 94% (95% CI 71-100; 16 of 17 patients) in patients who were ROS1 inhibitor naive and 40% (21-61; ten of 25) in patients who had previously received ROS1 inhibitor. In phase 2b cohort 1, the objective response rate was 88% (95% CI 76-95; 49 of 56 patients). In a prespecified exploratory analysis in 41 patients with CNS metastases at baseline, the objective response rate was 100% (95% CI 48-100; five of five patients) in patients in phase 2a who were ROS1 inhibitor naive, 40% (16-68; six of 15) in patients in phase 2a who had previously received ROS1 inhibitor, and 90% (70-99; 19 of 21) in patients in phase 2b cohort 1. Grade 3-4 treatment-related adverse events occurred in 33 (32%) of 104 patients; the most common were hyperglycaemia (12 [12%] patients) and electrocardiogram prolonged QT interval (six [6%]). Serious treatment-related adverse events occurred in 11 (11%) patients, with hyperglycaemia (six [6%]) being most common. No treatment-related adverse events led to death. INTERPRETATION: Foritinib showed systemic and intracranial antitumour activity and good tolerability in ROS1-inhibitor-naive patients with ROS1-rearranged NSCLC. Foritinib represents a promising treatment for these patients, especially in those with CNS metastases. FUNDING: Fosun Pharma, Wanbang Biopharmaceuticals, and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yang JJ, Zhou J, Liu SM, et al. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study. Lancet Respir Med. 2024. PMID: 39059398. doi:10.1016/S2213-2600(24)00171-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。